Naftali Timna, Lev Lihi Bar, Yablecovitch Doron, Half Elisabeth, Konikoff Fred M
Institute of Gastroenterology and Hepatology, Meir Medical Center, Kfar Saba affiliated with Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
Isr Med Assoc J. 2011 Aug;13(8):455-8.
The marijuana plant cannabis is known to have therapeutic effects, including improvement of inflammatory processes. However, no report of patients using cannabis for Crohn's disease (CD) was ever published.
To describe the effects of cannabis use in patients suffering from CD.
In this retrospective observational study we examined disease activity, use of medication, need for surgery, and hospitalization before and after cannabis use in 30 patients (26 males) with CD. Disease activity was assessed by the Harvey Bradshaw index for Crohn's disease.
Of the 30 patients 21 improved significantly after treatment with cannabis. The average Harvey Bradshaw index improved from 14 +/- 6.7 to 7 +/- 4.7 (P < 0.001). The need for other medication was significantly reduced. Fifteen of the patients had 19 surgeries during an average period of 9 years before cannabis use, but only 2 required surgery during an average period of 3 years of cannabis use.
This is the first report of cannabis use in Crohn's disease in humans. The results indicate that cannabis may have a positive effect on disease activity, as reflected by reduction in disease activity index and in the need for other drugs and surgery. Prospective placebo-controlled studies are warranted to fully evaluate the efficacy and side effects of cannabis in CD.
已知大麻植物具有治疗作用，包括改善炎症过程。然而，从未有过患者使用大麻治疗克罗恩病（CD）的报告。
描述大麻对克罗恩病患者的影响。
在这项回顾性观察研究中，我们检查了30例（26例男性）克罗恩病患者在使用大麻前后的疾病活动度、药物使用情况、手术需求和住院情况。克罗恩病的疾病活动度通过哈维·布拉德肖指数进行评估。
30例患者中，21例在使用大麻治疗后有显著改善。哈维·布拉德肖指数平均从14±6.7改善至7±4.7（P<0.001）。其他药物的需求显著减少。15例患者在使用大麻前的平均9年期间进行了19次手术，但在使用大麻的平均3年期间仅2例需要手术。
这是人类使用大麻治疗克罗恩病的首例报告。结果表明，大麻可能对疾病活动度有积极影响，这体现在疾病活动指数降低以及对其他药物和手术的需求减少。有必要进行前瞻性安慰剂对照研究，以全面评估大麻在克罗恩病中的疗效和副作用。
